87 related articles for article (PubMed ID: 25200903)
1. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
[TBL] [Abstract][Full Text] [Related]
2. Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012.
Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ
BMC Infect Dis; 2018 May; 18(1):215. PubMed ID: 29743015
[TBL] [Abstract][Full Text] [Related]
3. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection.
Forouzannia F; Hamadeh A; Passos-Castilho AM; Erman A; Yu A; Feng Z; Janjua NZ; Sander B; Greenaway C; Wong WWL
Liver Int; 2024 Jun; 44(6):1383-1395. PubMed ID: 38445848
[TBL] [Abstract][Full Text] [Related]
4. Mortality among British Columbians testing for hepatitis C antibody.
Yu A; Spinelli JJ; Cook DA; Buxton JA; Krajden M
BMC Public Health; 2013 Apr; 13():291. PubMed ID: 23547940
[TBL] [Abstract][Full Text] [Related]
5. Mortality related to HCV and other chronic liver diseases in Veneto (Italy), 2008-2021: Changes in trends and age-period-cohort effects.
Casotto V; Amidei CB; Saia M; Gregori D; Zanetto A; Fedeli U; Russo FP
Liver Int; 2024 Feb; 44(2):559-565. PubMed ID: 38031995
[TBL] [Abstract][Full Text] [Related]
6. Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada.
Samji H; Yu A; Wong S; Wilton J; Binka M; Alvarez M; Bartlett S; Pearce M; Adu P; Jeong D; Clementi E; Butt Z; Buxton J; Gilbert M; Krajden M; Janjua NZ
Int J Drug Policy; 2020 Oct; 86():102989. PubMed ID: 33091735
[TBL] [Abstract][Full Text] [Related]
7. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.
El-Kamary SS; Jhaveri R; Shardell MD
Clin Infect Dis; 2011 Jul; 53(2):150-7. PubMed ID: 21665867
[TBL] [Abstract][Full Text] [Related]
8. Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995-2016.
Bressler SS; Bruden D; Nolen LD; Bruce MG; Towshend-Bulson L; Spradling P; McMahon BJ
Can J Gastroenterol Hepatol; 2022; 2022():2573545. PubMed ID: 35178364
[TBL] [Abstract][Full Text] [Related]
9. Increase in alcohol related deaths: is hepatitis C a factor?
Henry JA; Moloney C; Rivas C; Goldin RD
J Clin Pathol; 2002 Sep; 55(9):704-7. PubMed ID: 12195003
[TBL] [Abstract][Full Text] [Related]
10. Complex differences in infection rates between ethnic groups in Scotland: a retrospective, national census-linked cohort study of 1.65 million cases.
Gruer LD; Cézard GI; Wallace LA; Hutchinson SJ; Douglas AF; Buchanan D; Katikireddi SV; Millard AD; Goldberg DJ; Sheikh A; Bhopal RS
J Public Health (Oxf); 2022 Mar; 44(1):60-69. PubMed ID: 33480434
[TBL] [Abstract][Full Text] [Related]
11. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Kohli A; Osinusi A; Sims Z; Nelson A; Meissner EG; Barrett LL; Bon D; Marti MM; Silk R; Kotb C; Gross C; Jolley TA; Sidharthan S; Petersen T; Townsend K; Egerson D; Kapoor R; Spurlin E; Sneller M; Proschan M; Herrmann E; Kwan R; Teferi G; Talwani R; Diaz G; Kleiner DE; Wood BJ; Chavez J; Abbott S; Symonds WT; Subramanian GM; Pang PS; McHutchison J; Polis MA; Fauci AS; Masur H; Kottilil S
Lancet; 2015 Mar; 385(9973):1107-13. PubMed ID: 25591505
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
[TBL] [Abstract][Full Text] [Related]
13. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
[TBL] [Abstract][Full Text] [Related]
14. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
16. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?
Innes H; Goldberg D; Dillon J; Hutchinson SJ
Gut; 2015 Nov; 64(11):1800-9. PubMed ID: 25378522
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
[TBL] [Abstract][Full Text] [Related]
18. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.
Saraswat V; Norris S; de Knegt RJ; Sanchez Avila JF; Sonderup M; Zuckerman E; Arkkila P; Stedman C; Acharya S; Aho I; Anand AC; Andersson MI; Arendt V; Baatarkhuu O; Barclay K; Ben-Ari Z; Bergin C; Bessone F; Blach S; Blokhina N; Brunton CR; Choudhuri G; Chulanov V; Cisneros L; Croes EA; Dahgwahdorj YA; Dalgard O; Daruich JR; Dashdorj NR; Davaadorj D; de Vree M; Estes C; Flisiak R; Gadano AC; Gane E; Halota W; Hatzakis A; Henderson C; Hoffmann P; Hornell J; Houlihan D; Hrusovsky S; Jarčuška P; Kershenobich D; Kostrzewska K; Kristian P; Leshno M; Lurie Y; Mahomed A; Mamonova N; Mendez-Sanchez N; Mossong J; Nurmukhametova E; Nymadawa P; Oltman M; Oyunbileg J; Oyunsuren Ts; Papatheodoridis G; Pimenov N; Prabdial-Sing N; Prins M; Puri P; Radke S; Rakhmanova A; Razavi H; Razavi-Shearer K; Reesink HW; Ridruejo E; Safadi R; Sagalova O; Sanduijav R; Schréter I; Seguin-Devaux C; Shah SR; Shestakova I; Shevaldin A; Shibolet O; Sokolov S; Souliotis K; Spearman CW; Staub T; Strebkova EA; Struck D; Tomasiewicz K; Undram L; van der Meer AJ; van Santen D; Veldhuijzen I; Villamil FG; Willemse S; Zuure FR; Silva MO; Sypsa V; Gower E
J Viral Hepat; 2015 Jan; 22 Suppl 1():6-25. PubMed ID: 25560839
[TBL] [Abstract][Full Text] [Related]
19. Impact of common risk factors of fibrosis progression in chronic hepatitis C.
Rüeger S; Bochud PY; Dufour JF; Müllhaupt B; Semela D; Heim MH; Moradpour D; Cerny A; Malinverni R; Booth DR; Suppiah V; George J; Argiro L; Halfon P; Bourlière M; Talal AH; Jacobson IM; Patin E; Nalpas B; Poynard T; Pol S; Abel L; Kutalik Z; Negro F
Gut; 2015 Oct; 64(10):1605-15. PubMed ID: 25214320
[TBL] [Abstract][Full Text] [Related]
20. Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
Aspinall EJ; Doyle JS; Corson S; Hellard ME; Hunt D; Goldberg D; Nguyen T; Falck-Ytter Y; Morgan RL; Smith B; Stoove M; Wiktor SZ; Hutchinson S
Eur J Epidemiol; 2015 Feb; 30(2):115-29. PubMed ID: 25385677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
